By: Emily MacHale
Tustin, CA – Integrium Executives are attending the 5th Microbiome R&D and Business Collaboration Forum in San Diego on November 2-3, 2017; with the collaboration of the 2nd Probiotics Congress: USA. Integrium Executives are excited to network and share ideas with the projected over 400 attendees and 70 speakers that will be involved in roundtables, panel discussions, networking events, and more. More specifically, Integrium is looking forward to learning more about the innovative opportunities involving the human microbiome: the gut, skin, oral, genetic disease states and beyond.
Integrium is heavily invested in the microbiome space, currently conducting various dermatology and gut microbiome studies. In addition, Integrium’s clinical Phase I - IV unit (Orange County Research Center) has thousands of pre-screened healthy volunteers that participate (or want to participate) in upcoming fecal sampling studies. Having better knowledge of the microbiome is important to understanding numerous existing genetic diseases. Many genetic diseases require their own unique approach, and grasping the ins and outs of the microbiome can impact the way we tackle these innovative drug development goals.
Actively participating in the 5th Microbiome R&D and Business Collaboration Forum allows Integrium to broaden goals and initiatives for microbiome-based disease cures, provides opportunity to dip into recent findings, and to stay in touch with industry trends. With that, investors are able to join and find potential partnerships with early-stage biotechs and start-ups.
Integrium is available for meetings all day on November 2, 2017 and encourages guests reach out to Emily MacHale, Associate Director of Marketing & Research at Emily.MacHale@integrium.com for any meeting requests.
Founded in 1998 by visionary clinical research thought leaders, Integrium is a fullservice Phase I-IV clinical CRO that specializes in a wide range of therapeutic areas. Integrium plays a key role in furthering new medical advancements by helping pharmaceutical companies design and execute clinical studies, ensuring they achieve their objectives on time, on budget, and with expected quality.
Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the New Chemical Entity, 5o5b2 and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include: Cardiovascular, Metabolic, Microbiome, Regenerative Medicine, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.
For more information on Integrium’s microbiome clinical studies and initiatives, please visit us online at: http://www.integrium.com/our-expertise/microbiome/
Check out our new website!
To learn more about Integrium, contact:
Associate Director of Marketing & Research